How resurrecting extinct species might impact medicine

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hey, it’s Meghana. Today, we see how the GLP-1s might be harnessed for Parkinson’s, we learn about species de-extinction efforts, and BIO’s CEO tells us why the U.S. needs to stay on top in biotech.

The need-to-know this morning

• Amylyx Pharmaceuticals is removing its ALS treatment, called Relyvrio, from the U.S. and Canadian markets, where the medicine is currently approved. The company’s decision comes weeks after the drug failed to show any benefits for patients in a large clinical trial.

GLP-1 drug shows potential in Parkinson’s

The potential of GLP-1 drugs stretches far past diabetes and obesity; now, a new study suggests one such drug could even be effective in treating Parkinson’s disease. The motor symptoms of patients in a Phase 2 trial testing lixisenatide, an older GLP-1 drug, didn’t worsen over the course of a year, in contrast to the patients on placebo, a NEJM study shows.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In